Cargando…

Increased efficacy of gefitinib on cisplatin-resistant wild-type epidermal growth factor receptor non-small cell lung cancer cells

BACKGROUND: Gefitinib is a first-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that has become first-line treatment for patients with mutant EGFR non-small cell lung cancer (NSCLC). Despite its anti-tumor activity, the benefit of gefitinib in patients with wild-typ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Amin, Cao, Weiya, Liu, Xueke, Zhang, Yinci, Ma, Yongfang, Xu, Ruyue, Tang, Xiaolong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798197/ https://www.ncbi.nlm.nih.gov/pubmed/35117912 http://dx.doi.org/10.21037/tcr-20-1441

Ejemplares similares

Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells
por: Li, Amin, et al.
Publicado: (2020)

BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy
por: Cao, Weiya, et al.
Publicado: (2021)

LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells
por: Ma, Yongfang, et al.
Publicado: (2021)

LY-294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF-1α pathway
por: Xu, Ruyue, et al.
Publicado: (2021)

RETRACTED ARTICLE: The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation DNA repair pathway
por: Tang, Xiaolong, et al.
Publicado: (2020)

Retraction Note: The PI3K/mTOR Dual Inhibitor BEZ235 Nanoparticles Improve Radiosensitization of Hepatoma Cells Through Apoptosis and Regulation DNA Repair Pathway
por: Tang, Xiaolong, et al.
Publicado: (2021)

hGC33-Modified and Sorafenib-Loaded Nanoparticles have a Synergistic Anti-Hepatoma Effect by Inhibiting Wnt Signaling Pathway
por: Shen, Jing, et al.
Publicado: (2020)

Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic non-small cell lung cancer
por: Huang, Ji-Jie, et al.
Publicado: (2015)

Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)

Gefitinib in treatment of metastatic non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR)
por: Singh, Charu
Publicado: (2014)

Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
por: Yang, Hua, et al.
Publicado: (2016)

Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation
por: Nurwidya, Fariz, et al.
Publicado: (2016)

Assessing efficacy and safety of stereotactic body radiation therapy for oligometastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) wild type
por: Hu, Xiaolong, et al.
Publicado: (2021)

Gefitinib for Epidermal Growth Factor Receptor Activated Osteoarthritis Subpopulation Treatment
por: Sun, Heng, et al.
Publicado: (2018)

Restricting extracellular Ca(2+) on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca(2+) response, which consequently enhances gefitinib sensitivity
por: Kim, Mi Seong, et al.
Publicado: (2020)

Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
por: SONG, ZHENGBO, et al.
Publicado: (2013)

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
por: Jung, Hyun Ae, et al.
Publicado: (2020)

Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells
por: Li, Jiajin, et al.
Publicado: (2016)

Heterogeneity of the resistance to gefitinib treatment in a non‐small cell lung cancer patient with active epidermal growth factor receptor mutation
por: Xu, Chong‐Rui, et al.
Publicado: (2016)

In Vitro and in Vivo Efficacy of NBDHEX on Gefitinib-resistant Human Non-small Cell Lung Cancer
por: Sha, Huanhuan, et al.
Publicado: (2020)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors
por: Blackledge, G, et al.
Publicado: (2004)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription
por: Yuan, Weiwei, et al.
Publicado: (2019)

Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR
por: Han, Shu-Yan, et al.
Publicado: (2014)

Randomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib Treatment
por: Xue, Cong, et al.
Publicado: (2015)

The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
por: Al-Keilani, Maha S, et al.
Publicado: (2018)

Enhanced gefitinib‐induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia‐mutated kinase inhibition in non‐small‐cell lung cancer cells
por: Misumi, Keizo, et al.
Publicado: (2016)

Increased glutamine anabolism sensitizes non-small cell lung cancer to gefitinib treatment
por: Wang, Liang, et al.
Publicado: (2018)

Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation‐positive non‐small cell lung cancer
por: Sun, Hongyan, et al.
Publicado: (2015)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
por: Asahina, H, et al.
Publicado: (2006)

Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer
por: Parra, H S, et al.
Publicado: (2004)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
por: Liu, Kejun, et al.
Publicado: (2020)

The EGFR Inhibitor Gefitinib Enhanced the Response of Human Oral Squamous Cell Carcinoma to Cisplatin In Vitro
por: Khalil, Ashraf, et al.
Publicado: (2017)

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
por: Horiike, A, et al.
Publicado: (2011)

Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in vitro and in vivo
por: Li, Tao, et al.
Publicado: (2021)

Overexpression of CTEN is associated with gefitinib resistance in non-small cell lung cancer
por: Lu, Xiangdong, et al.
Publicado: (2021)

Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma
por: Tang, Xiaolong, et al.
Publicado: (2018)

Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
por: Araki, Takuya, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_a4esguanbqv9uctt5j5mmmk4pg